Video

Dr. Schoenfeld on Preventing Immune Suppression With Radiation and Immunotherapy Combos

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses challenges with immune suppression with radiation and immunotherapy combinations.

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses challenges with immune suppression with radiation and immunotherapy combinations.

Currently radiation in the locally advanced setting is given in small daily doses over 4 to 7 weeks, says Schoenfeld. There is a concern, especially when the radiation is given to a large portion of the body, that it can act as an immune suppresser. This may not be the best way to radiation in combination with immunotherapy.

However, in the past several years there has been a dramatic increase in focal radiation, including stereotactic body radiotherapy. Because this is a much more focused type of radiation it may better combine with immunotherapy, says Schoenfeld.

Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD